Is Pfizer-BioNTech’s Kovid-19 vaccine fully effective in the 12-15 age group? Description has arrived

LAST MINUTE: Pfizer announced that advanced clinical trials have shown that two doses of vaccine developed in partnership with BionTech company prevent Kovid-19 infection 100 percent in the 12-15 age group within 7 days to 4 months after the second dose.

The company announced that no serious side effects were found in 2,228 subjects who participated in the 3rd phase experiments.

It has been learned that the said data will be used in the application for full approval of the Pfizer/BionTech vaccine, which the company will make to the US Food and Drug Administration (FDA), for the 12-15 age group.

The vaccine was given emergency use approval for the 12-15 age group by the FDA in May.

Source: A HABER by

*The article has been translated based on the content of A HABER by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!